BioCentury
ARTICLE | Financial News

Dova, Aileron seek NASDAQ listings

June 5, 2017 8:12 PM UTC

Oncology play Aileron Therapeutics Inc. (Cambridge, Mass.) and rare disease company Dova Pharmaceuticals Inc. (Durham, N.C.) each proposed IPOs on NASDAQ.

Stapled peptide therapeutic company Aileron filed to raise $69 million in an offering underwritten by BofA Merrill Lynch, Jefferies, William Blair and Canaccord. Its lead program, ALRN-6924, is in a Phase I trial in advanced solid tumors or lymphomas, a Phase IIa trial in peripheral T cell lymphoma, a Phase I trial as monotherapy to treat acute myelogenous leukemia (AML) and advanced myelodysplastic syndrome (MDS), and a Phase Ib trial in AML and MDS. The company plans to report interim data from the Phase IIa trial in 1H18 and expects to complete enrollment in the AML and MDS trials in 4Q17...